Abstract
Editorial
Highlights
There is a continuing need for new antibacterial drugs to deal with the burgeoning of bacterial pathogens resistant to the existing armamentarium of antibacterial drugs, compromising their effectiveness; emerging pathogens are considered to be a major microbiologic public health threat
These issues have been addressed with the modification of existing antibiotic classes or the search for new structural classes
Today the clinical pipeline is predominantly occupied by derivatives of established classes, there are some novel entries in development [1]
Summary
There is a continuing need for new antibacterial drugs to deal with the burgeoning of bacterial pathogens resistant to the existing armamentarium of antibacterial drugs, compromising their effectiveness; emerging pathogens are considered to be a major microbiologic public health threat.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
